The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing

Trombetta, Claudia Maria; Marchi, Serena; Montomoli, Emanuele

doi:10.1080/14760584.2022.2085565

Cited by 15 publications

(26 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rBV-produced VLPs from serum-free insect cell cultures are beneficial to VLP vaccine technology. RSV VLP production utilizing the rBV-insect cell expression system is FDA approved for human use, and the high levels of VLPs generated from suspension cultures of insect cells will facilitate large-scale vaccine production ( 57 , 58 , 69 ). Therefore, the work presented in this study provides a novel, promising strategy for the development of RSV vaccine candidates.…”

Section: Discussionmentioning

confidence: 99%

Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice

et al. 2022

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a serious respiratory pathogen in infants and young children worldwide. Currently, no licensed RSV vaccines are available. In this study, we explored stable prefusion conformation virus-like particles (Pre-F VLPs) as RSV vaccine candidates. RSV fusion (F) protein mutants were constructed to form stabilized Pre-F or postfusion (Post-F) configurations. VLPs containing Pre-F or Post-F protein were generated using a recombinant baculovirus (rBV)-insect cell expression system. The assembly and immunological properties of Pre-F or Post-F VLPs were investigated. Pre-F and Post-F VLPs contained antigenic sites Ø and I of pre- and postfusion conformations, respectively. Compared with Post-F VLPs, immunization with Pre-F VLPs elicited upregulation of IFN-γ, IL-2 and IL-10 and downregulation of IL-4 and IL-5 cytokine production in mice. A high percentage of CD25+ Foxp3+ cells or a low percentage of IL-17A-producing cells among CD4+ T cells was observed in the lungs of mice vaccinated with Pre-F VLPs. Importantly, immunization with Pre-F VLPs induced a high level of RSV neutralizing antibody and a balanced immune response, which protected mice against RSV infection without evidence of immunopathology. Our results suggested that Pre-F VLPs generated from rBV-insect cells represent promising RSV vaccine candidates.

show abstract

Section: Discussionmentioning

confidence: 99%

Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Moreover, Flublok is active against three IV strains: Two Influenza A strains and an Influenza B strain 92 . The trivalent flu vaccine was approved by the FDA in 2013 for the prevention of flu in persons aged 18–49 years in the United States 47,93 . A four‐component flu vaccine has also been developed in the I/BC system to protect against two influenza A strains (A/H1N1 and A/H3N2) and two Influenza B lineages (B/Yamagata and B/Victoria) 120 .…”

Section: Virus‐like Particles For Vaccine Developmentmentioning

confidence: 99%

Virus‐like particles as powerful vaccination strategy against human viruses

Hadj Hassine,

Ben M'hadheb,

Almalki

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

Nowadays, viruses are not only seen as causative agents of viral infectious diseases but also as valuable research materials for various biomedical purposes, including recombinant protein production. When expressed in living or cell‐free expression systems, viral structural proteins self‐assemble into virus‐like particles (VLPs). Mimicking the native form and size of viruses and lacking the genetic material, VLPs are safe and highly immunogenic and thus can be exploited to develop antiviral vaccines. Some vaccines based on VLPs against various infectious pathogens have already been licenced for human use and are available in the commercial market, the latest of which is a VLP‐based vaccine to protect against the novel Coronavirus. Despite the success and popularity of VLP subunit vaccines, many more VLPs are still in different stages of design, production, and approval. There are still many challenges that require to be addressed in the future before this surface display system can be widely used as an effective vaccine strategy in combating infectious diseases. In this review, we highlight the use of structural viral proteins to produce VLPs, emphasising their intrinsic properties, structural classification, and main expression host systems. We also compiled the recent scientific literature about VLP‐based vaccines to underline the recent advances in their application as a vaccine strategy for preventing and fighting virulent human pathogens. Finally, we presented the key challenges and possible solutions for VLP‐based vaccine production.

show abstract

“…This system also has significant advantages in enhanced protein stability and vaccine safety. [33][34][35][36][37][38] Plant-based expression system also provides a high level of safety and can facilitate regulatory approvals without costly infrastructure. 39,40 Proteins expressed from the chloroplast genome can retain their structure and function at room temperature, enabling long-term Plasma B cells produce specific neutralizing antibodies aimed at eliminating the virus storage in non-refrigerated environments.…”

Section: Current Covid-19 Preventive and Therapeutic Strategies Curre...mentioning

confidence: 99%

Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period

Ao,

He,

Liu

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant casualties and put immense strain on public health systems worldwide, leading to economic recession and social unrest. In response, various prevention and control strategies have been implemented globally, including vaccine and drug development and the promotion of preventive measures. Implementing these strategies has effectively curbed the transmission of the virus, reduced infection rates, and gradually restored normal social and economic activities. However, the mutations of SARS-CoV-2 have led to inevitable infections and reinfections, and the number of deaths continues to rise. Therefore, there is still a need to improve existing prevention and control strategies, mainly focusing on developing novel vaccines and drugs, expediting medical authorization processes, and keeping epidemic surveillance. These measures are crucial to combat the Coronavirus disease (COVID-19) pandemic and achieve sustained, long-term prevention, management, and disease control. Here, we summarized the characteristics of existing COVID-19 vaccines and drugs and suggested potential future directions for their development. Furthermore, we discussed the COVID-19-related policies implemented over the past years and presented some strategies for the future.

show abstract

The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing

Cited by 15 publications

References 97 publications

Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice

Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice

Virus‐like particles as powerful vaccination strategy against human viruses

Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period

Contact Info

Product

Resources

About